Skip to content
HowShorted

ATOSSA THERAPEUTICS, INC. short interest in 2025

In 2025, ATOSSA THERAPEUTICS, INC.'s disclosed short interest ran from 6.94% of shares outstanding on 15 Jan 2025 to 1.79% on 31 Dec 2025, a change of -5.15 percentage points. The year's high was 7.35% on 31 Jan 2025 and its low 1.02% on 31 Oct 2025, averaging 4.06% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.92 days on 28 Feb 2025. Full history: ATOSSA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ATOSSA THERAPEUTICS, INC. in 2025

2025 in figures

Start of year
6.94% (15 Jan 2025)
End of year
1.79% (31 Dec 2025)
Change
-5.15 pp
High
7.35% (31 Jan 2025)
Low
1.02% (31 Oct 2025)
Average
4.06%
Highest days to cover
16.92 (28 Feb 2025)
SEC filings marked
8

Every report in 2025

ATOSSA THERAPEUTICS, INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20256.94%10.77
31 Jan 20257.35%11.37
14 Feb 20257.15%13.96
28 Feb 20257.05%16.92
14 Mar 20256.82%16.51
31 Mar 20256.27%15.0210-K filed, results (8-K)
15 Apr 20255.90%9.59
30 Apr 20255.52%10.78
15 May 20255.53%8.9910-Q filed, results (8-K)
30 May 20255.90%11.36
13 Jun 20255.74%11.66
30 Jun 20253.61%1.96
15 Jul 20253.16%6.16
31 Jul 20252.95%2.13
15 Aug 20252.83%5.4210-Q filed, results (8-K)
29 Aug 20252.77%7.98
15 Sep 20252.17%5.42
30 Sep 20251.82%3.84
15 Oct 20251.06%1.00
31 Oct 20251.02%1.82
14 Nov 20251.07%2.6110-Q filed, results (8-K)
28 Nov 20251.20%3.07
15 Dec 20251.77%1.56
31 Dec 20251.79%1.87

See also: ATOSSA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.